Publication: Cross over placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients
Issued Date
1999-06-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-0033139867
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.30, No.2 (1999), 307-310
Suggested Citation
Nisarat Opartkiattikul, Sathien Sukpanichnant, Yoshinori Funahara, Akinobu Sumiyoshi, Wanchai Wanachiwanawin, Noriyuki Tatsumi, Suthat Fucharoen Cross over placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.30, No.2 (1999), 307-310. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25634
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cross over placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients
Other Contributor(s)
Abstract
An attempt was made to find better symptomatic treatment for beta-thalassemia/hemoglobin E (β-thal/Hb E) patients in order to reduce their blood demand. Oral administration of dilazep was prescribed for these patients and a clinical trial was conducted over a 2-year period as a cross over placebo control study. Seventeen β-thal/Hb E patients were enrolled in the study. All of them received dilazep and placebo for 10 months at different periods of time and were taken care of by the same doctor throughout the study. The blood demand of the same patients during the period of receiving dilazep with the period of receiving placebo, was 1.5 ± 1.8 U/10 months versus 2.2 ± 2.6 U/10 months, respectively. Thus dilazep showed a benefit in decreasing the blood demand by about 50% although the results did not reach statistical significance (p = 0.1). There was a statistical difference ir hemoglobin concentration of the patients receiving dilazep compared with placebo (p = 0.038). While receiving dilazep the mean ± SD hemoglobin level was 5.82 ± 0.8 g/dl, significantly higher than while receiving placebo (5.66 ± 0.9 g/dl) ( p = 0.038). The liver, and renal function tests, and cardiac enzyme levels of the patients showed no significant changes throughout the study. However, one case had a problem with bleeding following tooth extraction whilst receiving dilazep and needed 1 unit of blood transfusion. In conclusion, administration of dilazep to patients with β-thal/Hb E increased the patients' hemoglobin and reduced their blood demand with few side effects.